WO2010057710A2 - Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations - Google Patents

Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations Download PDF

Info

Publication number
WO2010057710A2
WO2010057710A2 PCT/EP2009/062582 EP2009062582W WO2010057710A2 WO 2010057710 A2 WO2010057710 A2 WO 2010057710A2 EP 2009062582 W EP2009062582 W EP 2009062582W WO 2010057710 A2 WO2010057710 A2 WO 2010057710A2
Authority
WO
WIPO (PCT)
Prior art keywords
heparan sulfate
cosmetological
weight
dermatological
salt
Prior art date
Application number
PCT/EP2009/062582
Other languages
English (en)
French (fr)
Other versions
WO2010057710A3 (en
WO2010057710A9 (en
Inventor
Luigi De Ambrosi
Original Assignee
Laboratori Derivati Organici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020117013681A priority Critical patent/KR101669528B1/ko
Priority to DK09783522.7T priority patent/DK2346573T3/da
Priority to JP2011536799A priority patent/JP2012509289A/ja
Priority to US13/129,030 priority patent/US9440099B2/en
Priority to PL09783522T priority patent/PL2346573T3/pl
Priority to EP09783522.7A priority patent/EP2346573B1/de
Priority to ES09783522.7T priority patent/ES2507495T3/es
Priority to SI200931013T priority patent/SI2346573T1/sl
Application filed by Laboratori Derivati Organici Spa filed Critical Laboratori Derivati Organici Spa
Publication of WO2010057710A2 publication Critical patent/WO2010057710A2/en
Publication of WO2010057710A3 publication Critical patent/WO2010057710A3/en
Publication of WO2010057710A9 publication Critical patent/WO2010057710A9/en
Priority to HRP20140862AT priority patent/HRP20140862T1/hr
Priority to US15/228,150 priority patent/US20160338935A1/en
Priority to US15/722,448 priority patent/US20180028427A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to a new process for the purification of heparan sulfate.
  • the present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.
  • Heparans are extracted from heparinoids which constitutes a byproduct in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGs); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O- sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.
  • GAGs glycosaminoglycanes
  • the present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti- wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions. [0005] In a further embodiment, the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.
  • the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.
  • the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate.
  • purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.
  • the purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.
  • the anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, LewatitTM S 6328 A.
  • the adsorption is performed by mixing a sufficient amount of resin beads.
  • the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.
  • heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate.
  • Suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate.
  • the pH of the salt solution is preferably comprised between 7.0 and 10.0.
  • the concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate.
  • a preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.
  • heparan sulfate is optionally further passed on a cationic resin and on a anionic resin.
  • a cationic resin is Amberlite Forte IR 120TM.
  • An example of a suitable cationic resin is Amberlite Forte IRA 410TM.
  • a preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.
  • the cosmetological compositions according to the invention comprise from 0.01 % by weight to 5 % by weight of heparan sulfate, more preferably from 0.05 % by weight to 2 % by weight, even more preferably from 0.1 % by weight to 1.0 % by weight.
  • the molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.
  • the cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.
  • compositions according to the present invention are used as anti-age product.
  • Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.
  • Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance.
  • the increase in protein amount for cell stimulates the ability of fibroblasts to synthetize collagen and elastin.
  • Another claim for anti-aging and protective cosmetics is their activity in counteracting oxidative stress and free-radicals release in the skin.
  • Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive
  • Oxygen Species (ROS) formation damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.
  • compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.
  • M w Molecular mass (M w ) was determined by size exclusion chromatography (European Pharmacopoeia 4 th ed. : 2.2.30 and 2.2.46 for chromatography techniques and 01/2002:0828 p.1297 for method).
  • NC negative control
  • PC positive control
  • HS heparan sulphate sodium salt
  • the test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for
  • the tested substance was an emulsion of the following composition : aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • Placebo was an emulsion of the following composition : aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • T 0 basal value, value of Melanin Index before the application of substance.
  • Basophil cells when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.
  • substances such as histamine, leukotriens, proteolytic enzymes as hexosaminidase
  • Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance.
  • the in vitro lenitive effect of HS was detected by measurement of the release of ⁇ -hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).
  • the negative control was represented by untreated cells (cells without any substance).
  • the positive control was represented by basophil degranulation stimul (by crosslinking the receptor Fc ⁇ RI with a specific polyclonal antibody against to the ⁇ -chain stimulate the degranulation).
  • the maximal stimulation is : cell treated with 1% Triton X-IOO. The results are reported as Optical Density (OD) at 405 nm.
  • ⁇ -hexosaminidase "natural" level, level without any contact with irritant substance is 0.054 (OD at 450 nm).
  • HS alone has the same effect of negative control, that means leaves the cell with their "natural" level of ⁇ -hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.
  • the test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm 2 on the back of each volunteer : one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2mg of substance) on tested area (1 cm 2 ) [as per Colipa guideline]. Total time : 60 minutes after application
  • Tested substance was an emulsion of following composition : aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • Placebo was an emulsion of following composition : aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • the transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator.
  • EI Erythema Index by Mexameter MX 18
  • o T 0 basal value
  • value of Erythema Index after UVB radiation and before the application of substance o Ti5 -value of Erythema Index after 15 minutes from substance application
  • o T 30 -value of Erythema Index after 30 minutes from substance application
  • o T 6 O -value of Erythema Index after 60 minutes from substance application
  • the antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (I' 30"), for 3 minutes (3') and for 4 minutes and 30 seconds (4' 30"), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%).
  • the negative control (NC) was: untreated cells (cells without any substance).
  • the positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).
  • Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect. The efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C. The efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4' 30").
  • the mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
  • the negative control (NC) is represented by untreated cells
  • the positive control (PC) is : EGF (Epidermal Growth Factor) (10 ⁇ g/ml) (0.001%).
  • heparan sulphate sodium salt shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP2009/062582 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations WO2010057710A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES09783522.7T ES2507495T3 (es) 2008-11-20 2009-09-29 Uso de sulfato de heparano en preparaciones cosmetológicas y dermatológicas
JP2011536799A JP2012509289A (ja) 2008-11-20 2009-09-29 ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用
US13/129,030 US9440099B2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
PL09783522T PL2346573T3 (pl) 2008-11-20 2009-09-29 Wykorzystanie siarczanu heparanu w kosmetycznych i dermatologicznych preparatach
EP09783522.7A EP2346573B1 (de) 2008-11-20 2009-09-29 Verwendung von heparansulfat in kosmetologischen und dermatologischen zubereitungen
KR1020117013681A KR101669528B1 (ko) 2008-11-20 2009-09-29 헤파란 술페이트의 정제 방법 및 미용학적 및 피부학적 제제에서 그의 용도
SI200931013T SI2346573T1 (sl) 2008-11-20 2009-09-29 Uporaba heparan sulfata v kozmetiäśnih in dermatoloĺ kih pripravkih
DK09783522.7T DK2346573T3 (da) 2008-11-20 2009-09-29 Anvendelse af heparansulfat i kosmetologiske og dermatologiske præparater
HRP20140862AT HRP20140862T1 (hr) 2008-11-20 2014-09-11 Uporaba heparan sulfata u kozmetiäśkim i dermatološkim pripravcima
US15/228,150 US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/722,448 US20180028427A1 (en) 2008-11-20 2017-10-02 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169547 2008-11-20
EP08169547.0 2008-11-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/129,030 A-371-Of-International US9440099B2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/228,150 Continuation US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Publications (3)

Publication Number Publication Date
WO2010057710A2 true WO2010057710A2 (en) 2010-05-27
WO2010057710A3 WO2010057710A3 (en) 2011-06-03
WO2010057710A9 WO2010057710A9 (en) 2011-08-18

Family

ID=41587870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/062582 WO2010057710A2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Country Status (14)

Country Link
US (3) US9440099B2 (de)
EP (2) EP2346573B1 (de)
JP (3) JP2012509289A (de)
KR (1) KR101669528B1 (de)
DK (2) DK2679278T3 (de)
ES (2) ES2650937T3 (de)
HR (2) HRP20140862T1 (de)
HU (1) HUE035362T2 (de)
LT (1) LT2679278T (de)
NO (1) NO2679278T3 (de)
PL (2) PL2679278T3 (de)
PT (2) PT2346573E (de)
SI (2) SI2346573T1 (de)
WO (1) WO2010057710A2 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016080915A1 (en) * 2014-11-19 2016-05-26 Agency For Science, Technology And Research Cosmetic use of heparan sulphate
ITUB20160156A1 (it) * 2016-02-05 2017-08-05 Laboratori Derivati Organici Spa Composizioni comprendenti una miscela di glicosamminoglicani e loro uso in composizioni cosmetiche e dermatologiche
US10266612B2 (en) 2013-05-16 2019-04-23 Agency For Science, Technology And Research Heparan sulphates
US10471091B2 (en) 2014-11-19 2019-11-12 Agency For Science, Technology And Research Heparan sulphates for use in repair and/or regeneration of skin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2346573T1 (sl) * 2008-11-20 2014-10-30 Laboratori Derivati Organici S.P.A. Uporaba heparan sulfata v kozmetiäśnih in dermatoloĺ kih pripravkih
FR3000067B1 (fr) * 2012-12-21 2016-05-13 Oreal Composes c-xylosides ,compositions et leur utilisation pour depigmenter la peau
CN108329405B (zh) * 2018-02-08 2020-06-23 黄石市典雅生物科技有限公司 一种树脂吸附状态下保护及纯化肝素钠的方法
CN111909288B (zh) * 2020-08-13 2021-09-03 山东辰龙药业有限公司 一种肝素钠的精制方法
KR20220096932A (ko) 2020-12-31 2022-07-07 주식회사 유연테크 분진제거와 제습기능이 결합된 제습 싸이크론 건조기

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902798A (en) * 1994-07-19 1999-05-11 Medicarb Ab Method of promoting dermal wound healing with chitosan and heparin or heparin sulfate
WO2009068215A1 (en) * 2007-11-27 2009-06-04 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150209A (ja) * 1986-12-15 1988-06-22 Kanebo Ltd 皮膚化粧料
IT1212143B (it) * 1987-06-26 1989-11-08 Crinos Industria Farmaco Composizione ad attivita'tricogena.
JPH06104620B2 (ja) * 1987-07-15 1994-12-21 鐘紡株式会社 皮膚化粧料
JPH0696514B2 (ja) * 1987-07-15 1994-11-30 鐘紡株式会社 皮膚化粧料
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
FR2643909B1 (fr) * 1989-03-03 1993-01-22 Bioetica Sa Composition de base pour la preparation d'une composition cosmetique formant composition capillaire et composition cosmetique formant composition capillaire ainsi preparee, contenant de l'heparine ou de l'heparane sulfate
JPH03161416A (ja) * 1989-11-21 1991-07-11 Kanebo Ltd 皮膚化粧料
JP2931083B2 (ja) * 1990-11-22 1999-08-09 ポーラ化成工業株式会社 皮膚化粧料
JPH05310548A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
GB9318288D0 (en) * 1993-09-03 1993-10-20 Nycomed Imaging As Improvements in or relating to contrast agents
JPH0899861A (ja) * 1994-09-30 1996-04-16 Kose Corp 皮膚外用剤
US5989874A (en) * 1995-03-27 1999-11-23 Tayca Corporation Humectant, antistatic agent, dispersant and film-forming agent having polysaccharide as active principle, preparation process of polysaccharides, and Kliebsiella ocytoca TNM-3 strain
RU2176509C2 (ru) * 1995-09-19 2001-12-10 Сейкагаку Корпорейшн Средство, усиливающее противовоспалительное действие иммунодепрессанта (варианты), способ усиления противовоспалительного действия иммунодепрессанта, способ лечения воспаления
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JP3687277B2 (ja) * 1997-06-10 2005-08-24 サンスター株式会社 美白化粧料
GB9913237D0 (en) * 1999-06-08 1999-08-04 K C L Enterprises Limited Product
JP4754066B2 (ja) * 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP2003171256A (ja) * 2001-12-03 2003-06-17 Nonogawa Shoji Kk 皮膚外用剤
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
US20070129430A1 (en) * 2003-10-07 2007-06-07 Satomi Miyata Agent for enhancing the production of collagen, their preparation and use
DE102004036689A1 (de) * 2004-07-28 2006-03-23 Henkel Kgaa Rückstandsarmer Deodorant- oder Antitranspirant-Stift auf Basis einer Öl-in-Wasser-Dispersion
WO2007044945A2 (en) * 2005-10-13 2007-04-19 Gu, Jennifer, L. Mineral collagen chelates and methods of making and using same
JP2007254316A (ja) * 2006-03-22 2007-10-04 Seikagaku Kogyo Co Ltd Ｈａマトリックス形成阻害剤
JP4564471B2 (ja) * 2006-07-06 2010-10-20 株式会社コーセー 外用に適する組成物
SI2346573T1 (sl) * 2008-11-20 2014-10-30 Laboratori Derivati Organici S.P.A. Uporaba heparan sulfata v kozmetiäśnih in dermatoloĺ kih pripravkih

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902798A (en) * 1994-07-19 1999-05-11 Medicarb Ab Method of promoting dermal wound healing with chitosan and heparin or heparin sulfate
WO2009068215A1 (en) * 2007-11-27 2009-06-04 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEYTH R J ET AL: "Glycosaminoglycan distribution in substratum adhesion sites of aging human skin fibroblasts, including papillary and reticular subpopulations", MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 29, no. 2, 1 February 1985 (1985-02-01), pages 151-169, XP025196844, ISSN: 0047-6374, DOI: DOI:10.1016/0047-6374(85)90015-6 [retrieved on 1985-02-01] *
See also references of EP2346573A2 *
VAN HORSSEN J ET AL: "Heparan sulphate proteoglycans in Alzheimer's disease and amyloid@?related disorders", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 2, no. 8, 1 August 2003 (2003-08-01), pages 482-492, XP004810293, ISSN: 1474-4422, DOI: DOI:10.1016/S1474-4422(03)00484-8 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266612B2 (en) 2013-05-16 2019-04-23 Agency For Science, Technology And Research Heparan sulphates
WO2016080915A1 (en) * 2014-11-19 2016-05-26 Agency For Science, Technology And Research Cosmetic use of heparan sulphate
US10471091B2 (en) 2014-11-19 2019-11-12 Agency For Science, Technology And Research Heparan sulphates for use in repair and/or regeneration of skin
US10493012B2 (en) 2014-11-19 2019-12-03 Agency For Science, Technology And Research Cosmetic use of heparan sulphate
ITUB20160156A1 (it) * 2016-02-05 2017-08-05 Laboratori Derivati Organici Spa Composizioni comprendenti una miscela di glicosamminoglicani e loro uso in composizioni cosmetiche e dermatologiche

Also Published As

Publication number Publication date
US20180028427A1 (en) 2018-02-01
PT2346573E (pt) 2014-09-25
SI2679278T1 (en) 2018-02-28
JP6058588B2 (ja) 2017-01-11
WO2010057710A3 (en) 2011-06-03
HRP20171861T1 (hr) 2018-01-26
ES2650937T3 (es) 2018-01-23
DK2679278T3 (en) 2017-12-11
HRP20140862T1 (hr) 2014-11-07
US20160338935A1 (en) 2016-11-24
WO2010057710A9 (en) 2011-08-18
JP2014159488A (ja) 2014-09-04
US20110288047A1 (en) 2011-11-24
EP2679278A1 (de) 2014-01-01
PL2346573T3 (pl) 2014-12-31
NO2679278T3 (de) 2018-02-03
US9440099B2 (en) 2016-09-13
JP2012509289A (ja) 2012-04-19
EP2679278B1 (de) 2017-09-06
JP2017043638A (ja) 2017-03-02
HUE035362T2 (en) 2018-05-02
DK2346573T3 (da) 2014-10-06
EP2346573A2 (de) 2011-07-27
LT2679278T (lt) 2017-12-27
ES2507495T3 (es) 2014-10-15
SI2346573T1 (sl) 2014-10-30
PT2679278T (pt) 2017-12-13
PL2679278T3 (pl) 2018-02-28
EP2346573B1 (de) 2014-06-25
KR101669528B1 (ko) 2016-10-26
KR20110086734A (ko) 2011-07-29

Similar Documents

Publication Publication Date Title
US9440099B2 (en) Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
JP2014159488A5 (de)
US10426718B2 (en) Compositions and methods for treating hair loss and delaying aging of skin
EP1863430B1 (de) Zusammensetzung auf basis pflanzlicher extrakte von ajuga reptans zur vorbeugung von haarausfall, zur anregung des haarwuches und regulierung der talgproduktion
US10131717B2 (en) Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
KR102281774B1 (ko) 피부 재생 및 항염 효과가 있는 피부 상태 개선용 조성물
JP7233556B2 (ja) 皮膚美白外用剤におけるサリドロシド誘導体の使用
US20070167517A1 (en) Stabilized derivatives of ascorbic aicd
US20120245120A1 (en) Zinc sucrose octasulfates, their preparation, and pharmaceutical and cosmetic uses thereof
Lin et al. Efficient fucoidan extraction and purification from Sargassum cristaefolium and preclinical dermal biological activity assessments of the purified fucoidans
KR20140012456A (ko) 아케비아 사포닌-디를 포함하는 피부 상태 개선용 조성물
JP7073384B2 (ja) 化合物及び使用方法
CN113876788A (zh) 红景天苷水凝胶制剂及其制备方法和应用
KR20070096279A (ko) 소루쟁이 추출물을 함유하는 화장료 조성물
JP3120086B2 (ja) 白髪の防止及び白髪黒色化用毛髪化粧料
KR100616251B1 (ko) 녹용을 포함하는 한방 생약 복합 추출물을 함유한 화장료조성물
KR20040106616A (ko) 산삼 추출물 및 생약 추출물을 함유하는 피부 노화 방지용화장료 조성물
JPH05221834A (ja) 白髪の防止及び白髪黒色化用毛髪化粧料
JPH02268192A (ja) Ｄ―デソサミンのレチノイン酸エステル、その製法、ヒトまたは獣医用薬および化粧用組成物
JP3260467B2 (ja) 白髪の防止及び白髪黒色化用毛髪化粧料
JP2014515388A (ja) マグネシウムのスクロースオクタ硫酸エステル、その製造方法およびその医薬的および美容的使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09783522

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009783522

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011536799

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 20117013681

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13129030

Country of ref document: US